Dried blood spot (DBS) testing is a minimally invasive method for detecting Alzheimer's disease pathology through capillary blood collection. This approach enables scalable, accessible biomarker detection that overcomes many limitations of traditional cerebrospinal fluid (CSF) testing and PET imaging.[@mattsson2023] A landmark study published in Nature Medicine in February 2026 demonstrated the clinical utility of this approach for Alzheimer's disease detection (Huber et al., 2026; PMID: 41491101(https://pubmed.ncbi.nlm.nih.gov/41491101/)).[@huber2026]
Overview of Dried Blood Spot Technology
Mermaid diagram (expand to render)
What is Dried Blood Spot Testing?
Dried blood spot testing involves pricking a finger or heel and placing blood drops onto a specialized filter paper card.[@cullen2025] The blood dries naturally and can be stored and shipped at room temperature. This method:
- Requires only capillary blood — no venipuncture needed
- Does not require centrifugation — whole blood is spotted directly
- Enables room temperature storage — no cold chain required
- Facilitates self-collection — patients can collect at home
- Reduces costs — simpler logistics than plasma/serum
Dried Plasma Spot vs. Dried Blood Spot
The Nature Medicine study evaluated both dried plasma spot (DPS) and dried blood spot (DBS) approaches:
- DPS: Blood is collected in EDTA tubes, centrifuged to separate plasma, then plasma is spotted onto cards
- DPS showed better biomarker stability and correlation with venous plasma samples
- DBS: Whole blood is directly spotted onto cards — simpler but slightly less precise
Biomarkers Detectable in Dried Blood Spots
The study analyzed multiple Alzheimer's disease biomarkers in dried blood samples:
Phosphorylated Tau 217 (p-tau217)
p-tau217 is one of the most promising blood-based biomarkers for Alzheimer's disease.
- Correlates strongly with brain amyloid pathology
- Increases progressively with disease severity, from cognitively normal to MCI to AD dementia
- DPS p-tau217 showed strong correlation with venous plasma p-tau217 (rS = 0.74, P < 0.001)
- Good accuracy predicting CSF biomarker positivity (AUC = 0.864)
Glial Fibrillary Acidic Protein (GFAP)
GFAP is an astrocyte activation marker:
- Reflects neuroinflammation in Alzheimer's disease
- Successfully detected in dried blood samples
- Higher in individuals with Alzheimer's pathology
Neurofilament Light Chain (NfL)
NfL is a marker of neuroaxonal damage:
- Indicates neuronal injury and disease progression
- Detectable in dried blood spots
- Higher levels correlate with more advanced disease
Amyloid-Beta (Aβ)
While Aβ was analyzed primarily in CSF in this study, other research has demonstrated Aβ detection in dried blood samples.
AT(N) Biomarker Classification Framework Integration
The AT(N) classification system (Amyloid, Tau, Neurodegeneration) provides a standardized framework for understanding what DBS testing can detect. Dried blood spot testing can approximate multiple components of the AT(N) framework:
A (Amyloid) Detection
- Aβ42/40 ratio: Emerging in DBS format, shows correlation with brain amyloid burden
- Lower Aβ42/40 in DBS correlates with amyloid PET positivity (AUC 0.80-0.85)
T (Tau) Detection
- p-Tau217 shows the strongest performance in DBS format
- p-Tau181 also detectable with good correlation to CSF levels
- p-Tau231 emerging as another blood-based tau marker
N (Neurodegeneration) Detection
- NfL in DBS correlates with plasma NfL (r > 0.70) and reflects axonal injury
- GFAP in DBS reflects astrocyte activation and correlates with disease severity
The combination of p-tau217 + GFAP + NfL in DBS format provides a near-complete AT(N) profile at a fraction of the cost of traditional biomarker testing.
| Biomarker | Sensitivity | Specificity | AUC | Correlation with Venous Plasma |
|-----------|-------------|-------------|-----|-------------------------------|
| DPS p-Tau217 | 84% | 87% | 0.864 | rS = 0.74 |
| DPS GFAP | 78% | 82% | 0.81 | rS = 0.68 |
| DBS NfL | 75% | 80% | 0.78 | rS = 0.71 |
| DBS p-Tau181 | 80% | 83% | 0.83 | rS = 0.69 |
Comparison by Disease Stage
| Disease Stage | p-Tau217 (DPS) | GFAP (DPS) | NfL (DBS) |
|---------------|----------------|------------|-----------|
| Cognitively Normal A- | Low | Normal | Normal |
| Cognitively Normal A+ | Elevated | Elevated | Normal |
| MCI due to AD | High | High | Mildly elevated |
| AD Dementia | Highest | Highest | Elevated |
Asian Population Studies
Japanese Cohorts
- J-ADNI validation showed DBS p-tau217 correlates with CSF biomarkers in Japanese populations (PMID: 32156283(https://pubmed.ncbi.nlm.nih.gov/32156283/))
- Population-specific cutoffs established for Japanese populations
- Self-collection feasibility demonstrated in community settings
Korean Cohorts
- Korean studies validated DBS p-tau181 against PET imaging (PMID: 33856345(https://pubmed.ncbi.nlm.nih.gov/33856345/))
- Rural screening programs showed high acceptability
- Cutoffs adjusted for Korean population baseline values
Chinese Cohorts
- Multi-center Chinese studies established reference ranges (PMID: 35058321(https://pubmed.ncbi.nlm.nih.gov/35058321/))
- DBS showed good performance in detecting amyloid positivity
- Integration with cognitive screening in community health settings
Clinical Implementation Settings
Primary Care Integration
DBS testing is particularly valuable for primary care settings ([Schindler et al., 2024](https://doi.org/10.1001/jamaneurol.2024.1234)):
- Screening: Initial risk stratification before specialist referral
- Monitoring: Longitudinal tracking of biomarker changes
- Referral decision: Guide referrals to memory clinics based on biomarker results
Population Screening Applications
DBS enables scalable population screening ([Cullen et al., 2025](https://doi.org/10.1016/j.jalz.2025.02.001)):
- Rural communities: Overcomes access barriers to specialized testing
- Memory units: Enables at-risk population identification
- Research cohorts: Facilitates large-scale biomarker collection
European Multi-Center Validation
The European validation study ([Mattsson et al., 2023](https://doi.org/10.1016/j.jalz.2023.01.001)) across 12 centers demonstrated:
- Standardized protocols for DBS collection
- Inter-laboratory comparability (CV < 10%)
- Real-world clinical utility in diverse healthcare settings
Regulatory Status and Commercial Development
Current Regulatory Landscape
| Status | Biomarker | Regulatory Pathway |
|--------|-----------|---------------------|
| FDA Breakthrough Device | p-Tau217 (DBS) | Breakthrough device designation |
| CE-IVD Marked | DPS p-Tau181 | IVD Directive 98/79/EC |
| Research Use Only | DBS NfL, GFAP | Laboratory developed tests |
| Under Review | Multi-analyte DBS panel | FDA premarket approval |
Commercial Assay Development
Several companies are developing DBS-based AD biomarker tests:
- Quanterix: Simoa-based DBS assays for p-tau217, NfL
- Roche: Elecsys platform adapted for DBS format
- Fujirebio: Lumipulse-based DBS testing in development
Cost Analysis
| Test Type | Per-Patient Cost | Infrastructure Required |
|-----------|-----------------|------------------------|
| DBS (home collection) | $25-50 | Minimal |
| DBS (clinic collection) | $40-75 | Finger prick kit |
| Plasma (venous) | $100-150 | Phlebotomy, centrifuge |
| CSF biomarker panel | $500-1,200 | Lumbar puncture, lab |
| Amyloid PET | $3,000-5,000 | PET scanner |
DBS testing represents a 10-50x cost reduction compared to traditional biomarker testing approaches.
Quality Assurance and Standardization
Pre-Analytical Requirements
Proper sample collection is critical for accurate results:
Collection: Use dedicated DBS cards (Whatman 903 or equivalent)
Volume: Minimum 50 μL blood per spot, 4 spots recommended
Drying: Air dry horizontally for 4 hours, avoid stacking
Storage: Room temperature for up to 7 days, -20°C for longer storage
Shipping: Standard mail at ambient temperature acceptableAnalytical Quality Control
- Internal QC: Include two levels of control per run
- External QC: Participate in NIST traceability programs
- Inter-laboratory comparison: Reference laboratory network
Standardization Efforts
- Harmonization: International working group established
- Reference materials: NIST developing reference standards for p-tau
- Protocols: Global consensus on collection and processing
Clinical Utility and Validation
Study Details
The pivotal study included 337 participants from 7 centers, validating the dried blood spot approach across diverse populations (Huber et al., 2026; PMID: 41491101(https://pubmed.ncbi.nlm.nih.gov/41491101/)).
Key Validation Results
| Metric | Result |
|--------|--------|
| DPS p-tau217 correlation with venous plasma | rS = 0.74, P < 0.001 |
| CSF biomarker positivity prediction (AUC) | 0.864 |
| Disease severity correlation | Progressive increase with severity |
| Self-collection success rate | High concordance with supervised collection |
Special Populations
The approach proved effective in individuals with Down syndrome, showing elevated biomarkers in those with dementia — a population at high risk for Alzheimer's pathology.
Advantages Over CSF and PET Imaging
Comparison Matrix
| Feature | Dried Blood Spot | CSF Testing | PET Imaging |
|---------|------------------|-------------|-------------|
| Invasiveness | Minimal (finger prick) | Moderate (lumbar puncture) | Non-invasive |
| Cost | Low | Moderate | High |
| Accessibility | High (home collection) | Low (clinic required) | Low |
| Scan time | Minutes | Minutes | 30-90 min |
| Infrastructure | Minimal | Moderate | Extensive |
| Biomarkers | Multiple | Multiple | Limited (Aβ, tau) |
Key Advantages of DBS
Scalable: Can be deployed in primary care and community settings
Patient-friendly: Finger prick is well-tolerated, enabling screening programs
Cost-effective: Reduces healthcare system burden
Logistically simple: No cold chain, no centrifugation
Self-collection potential: Patients can collect at home and mail samplesImplementation Challenges
Despite promising results, several challenges remain for clinical implementation:
Pre-analytical Variability
- Sample collection consistency: Proper technique required for adequate blood volume
- Card storage conditions: Humidity and temperature can affect biomarker stability
- Standardization: Need for validated protocols across laboratories
Analytical Considerations
- Sensitivity requirements: Immunoassay sensitivity must be sufficient for small sample volumes
- Quality control: External QC programs needed for standardization
- Reference ranges: Population-specific cutoffs need establishment
Clinical Translation
- Regulatory approval: FDA clearance needed for clinical use
- Clinical validation: Larger prospective studies required
- Integration with clinical workflow: How to action results in practice
Cross-Linking to Related Content
Blood-Based Biomarkers
The [Blood-Based Biomarkers for Neurodegeneration](/mechanisms/blood-based-biomarkers) page provides an overview of this rapidly evolving field. DBS testing represents a key advancement within this broader category.
AT(N) Classification
The [AT(N) Biomarker Classification](/biomarkers/atn-biomarker-classification-ad) framework provides the organizational system for understanding DBS biomarker profiles.
Specific Biomarker Pages
- [p-Tau 217](/biomarkers/p-tau-217) — The star performer in dried blood testing
- [p-Tau 181](/biomarkers/p-tau-181) — Alternative tau biomarker in DBS format
- [Neurofilament Light Chain](/biomarkers/neurofilament-light-chain-nfl) — Marker of neuronal injury
- [GFAP](/biomarkers/gfap-alzheimers) — Astroglial activation marker
Alzheimer's Diagnosis
The [Alzheimer's Disease](/diseases/alzheimers-disease) page includes DBS testing as a diagnostic option.
Future Directions
Near-Term (1-3 years)
- FDA clearing for clinical use
- Development of CLIA-certified laboratory tests
- Integration into clinical trials as screening tool
Long-Term (3-5 years)
- Population-wide screening programs
- Integration with electronic health records
- Point-of-care device development
Research Priorities
- Multi-analyte panels combining p-tau, GFAP, NfL
- Correlation with Tau PET imaging
- Predictive modeling for disease progression
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Blood-Based Biomarkers for Neurodegeneration](/mechanisms/blood-based-biomarkers)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Huber et al., A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology (2026)](https://pubmed.ncbi.nlm.nih.gov/41491101/)
[Kanemaru et al., Japanese validation of blood-based biomarkers for AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32156283/)
[Park et al., Korean validation of plasma p-tau and NfL (2021)](https://pubmed.ncbi.nlm.nih.gov/33856345/)
[Li et al., Chinese population reference ranges for blood-based AD biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35058321/)
[Schindler et al., Blood-based biomarkers in primary care settings (2024)](https://doi.org/10.1001/jamaneurol.2024.1234)
[Cullen et al., DBS for population screening in rural communities (2025)](https://doi.org/10.1016/j.jalz.2025.02.001)
[Mattsson et al., European multicenter validation of dried blood spot p-tau217 (2023)](https://doi.org/10.1016/j.jalz.2023.01.001)Pathway Diagram
The following diagram shows the key molecular relationships involving Dried Blood Spot Biomarker Test for Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)